p19 INK4D/CDKN2D Antibody (A-4): sc-166774

p19 INK4D Antibody (A-4) is a mouse monoclonal IgG3 antibody that detects p19 INK4D in mouse and rat samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). p19 INK4D plays a crucial role in regulating the cell cycle by specifically inhibiting the kinase activities of cyclin-dependent kinases Cdk4 and Cdk6, which are essential for the transition from the G1 phase to the S phase of the cell cycle. This inhibition helps prevent uncontrolled cell proliferation, a hallmark of cancer. p19 INK4D expression is maximized during the S phase, and p19 INK4D overexpression can lead to G1 arrest, highlighting potential tumor suppressor properties. The gene encoding p19 INK4D is located on chromosome 9p21.3, a region frequently associated with chromosomal abnormalities in various human tumors, further underscoring p19 INK4D significance in cancer biology. With an ability to modulate cell cycle progression, p19 INK4D serves as a vital component in maintaining cellular homeostasis and offers insights into therapeutic strategies for cancer treatment.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p19 INK4D/CDKN2D Antibody (A-4) References:

1. Identification of calpain cleavage sites in the G1 cyclin-dependent kinase inhibitor p19(INK4d).  |  Joy, J., et al. 2006. Biol Chem. 387: 329-35. PMID: 16542156
2. Folding mechanism of an ankyrin repeat protein: scaffold and active site formation of human CDK inhibitor p19(INK4d).  |  Löw, C., et al. 2007. J Mol Biol. 373: 219-31. PMID: 17804013
3. Changes in CDKN2D, TP53, and miR125a expression: potential role in the evaluation of human amniotic fluid-derived mesenchymal stromal cell fitness.  |  Miranda-Sayago, JM., et al. 2012. Genes Cells. 17: 673-87. PMID: 22747700
4. Mutations in CDKN2C (p18) and CDKN2D (p19) may cause sporadic parathyroid adenoma.  |  Gluick, T., et al. 2013. Endocr Relat Cancer. 20: L27-9. PMID: 24127162
5. Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells via Forkhead Box M1 Suppression.  |  Lee, HA., et al. 2021. J Cancer. 12: 5086-5098. PMID: 34335925
6. The p19INK4D cyclin dependent kinase inhibitor gene is altered in osteosarcoma.  |  Miller, CW., et al. 1997. Oncogene. 15: 231-5. PMID: 9244358
7. Association of Stat3-dependent transcriptional activation of p19INK4D with IL-6-induced growth arrest.  |  Narimatsu, M., et al. 1997. Biochem Biophys Res Commun. 238: 764-8. PMID: 9325164
8. Structure of the cyclin-dependent kinase inhibitor p19Ink4d.  |  Luh, FY., et al. 1997. Nature. 389: 999-1003. PMID: 9353127
9. Interferon-alpha-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p19Ink4D and p21Cip1 in mouse macrophages.  |  Matsuoka, M., et al. 1998. Oncogene. 16: 2075-86. PMID: 9572488
10. Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.  |  Baumgartner, R., et al. 1998. Structure. 6: 1279-90. PMID: 9782052

The preferred p19 INK4D/CDKN2D antibody is p19 INK4D/CDKN2D Antibody (DCS-100): sc-56334.